Literature DB >> 8894363

HLA antigens in polymyalgia rheumatica in northern Sweden.

A Uddhammar1, B N Sojka, S Rantapää-Dahlqvist.   

Abstract

The HLA-A, B and DR antigens were analyzed with serological methods in 75 patients with polymyalgia rheumatica (PMR). In PMR patients the frequency of the HLA-DR4 antigen was significantly higher (62.1%) compared to blood donors (40%), p < 0.05, but did not differ from patients with seropositive rheumatoid arthritis (RA) from the same area (63.1%). In contrast, the frequency of HLA-B27 in the PMR patients (9.3%) was significantly lower compared to RA (27.2%), p < 0.01, but did not differ from blood donors (16.9%). There was no association between DR4 and disease affliction or severity in PMR. The increased frequency of HLA-B27 in RA but not in PMR in the population of northern Sweden suggests an immunogenetic difference between these two HLA-DR4 associated diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8894363     DOI: 10.1007/bf02229647

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

1.  Association of HLA-DR4 with a more progressive disease course in patients with rheumatoid arthritis. Results of a followup study.

Authors:  D van Zeben; J M Hazes; A H Zwinderman; A Cats; G M Schreuder; J D'Amaro; F C Breedveld
Journal:  Arthritis Rheum       Date:  1991-07

Review 2.  Functional domains on HLA-DR molecules: implications for the linkage of HLA-DR genes to different autoimmune diseases.

Authors:  C M Weyand; J J Goronzy
Journal:  Clin Immunol Immunopathol       Date:  1994-02

3.  Long-term follow-up of polymyalgia rheumatica: evidence for synovitis.

Authors:  L A Healey
Journal:  Semin Arthritis Rheum       Date:  1984-05       Impact factor: 5.532

4.  Increased prevalence of HLA-DR4 in giant-cell arteritis.

Authors:  J Barrier; J D Bignon; J P Soulillou; J Grolleau
Journal:  N Engl J Med       Date:  1981-07-09       Impact factor: 91.245

5.  HL-A27 and arthritis.

Authors:  H Isomäki; K Koota; J Martio; M Nissilä; A Tilikainen
Journal:  Ann Clin Res       Date:  1975-06

6.  Polymyalgia rheumatica and seronegative rheumatoid arthritis may be the same entity.

Authors:  L A Healey
Journal:  J Rheumatol       Date:  1992-02       Impact factor: 4.666

7.  Seronegative rheumatoid arthritis and HLA-DR4.

Authors:  K F al-Jarallah; W W Buchanan; A Sastry; D P Singal
Journal:  J Rheumatol       Date:  1994-02       Impact factor: 4.666

8.  An immunogenetic study of older age onset rheumatoid arthritis.

Authors:  R Terkeltaub; F Décary; J Esdaile
Journal:  J Rheumatol       Date:  1984-04       Impact factor: 4.666

9.  HLA B27 in the population of northern Sweden.

Authors:  A Bjelle; B Cedergren; S R Dahlqvist
Journal:  Scand J Rheumatol       Date:  1982       Impact factor: 3.641

10.  Clinical and pathologic studies of synovitis in polymyalgia rheumatica.

Authors:  C T Chou; H R Schumacher
Journal:  Arthritis Rheum       Date:  1984-10
View more
  4 in total

1.  HLA-DRB1 alleles associated with polymyalgia rheumatica in northern Italy: correlation with disease severity.

Authors:  C Salvarani; L Boiardi; V Mantovani; A Ranzi; F Cantini; I Olivieri; M Bragliani; E Collina; P Macchioni
Journal:  Ann Rheum Dis       Date:  1999-05       Impact factor: 19.103

Review 2.  Giant cell arteritis with ocular complications discovered simultaneously in two sisters.

Authors:  F Gros; J F Maillefert; A Behin; F Guignier; C Piroth; C Creuzot-Garcher; C Tavernier
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

3.  Polymyalgia rheumatica and colon malignacy: case report.

Authors:  Tatjana Kehler; Bozidar Curković
Journal:  Clin Rheumatol       Date:  2005-10-25       Impact factor: 2.980

Review 4.  Highlights in clinical medicine-Giant cell arteritis, polymyalgia rheumatica and Takayasu's arteritis: pathogenic links and therapeutic implications.

Authors:  Antonio Giovanni Solimando; Angelo Vacca; Franco Dammacco
Journal:  Clin Exp Med       Date:  2021-11-06       Impact factor: 5.057

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.